ArticleJournal of translational autoimmunity2026
Type I interferon upregulates IL-18RAP in neutrophils to enhance chemotaxis and bactericidal activity in autoimmune liver diseases.
Article in Journal of translational autoimmunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Given the established association of interleukin-18 (IL-18) and IL-18 receptor accessory protein (IL-18RAP) with autoimmune liver diseases (AILD), while their specific mechanism remains unclear, this study aimed to investigate the expression and functional significance of IL-18RAP in neutrophils from patients with AILD. Methods: The expression levels of IL-18RAP were determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blot. Serum type I interferon (IFN) concentrations were measured by enzyme-linked immunosorbent assay (ELISA). Results: IL-18RAP mRNA and protein expression levels were increased in patients with AILD. After IL-18 stimulation, the chemotaxis index and nitroblue tetrazolium (NBT) reduction rate of neutrophils in the AILD group increased ( Conclusion: Elevated IL-18RAP expression in AILD patients enhanced the chemotactic, phagocytic, and bactericidal functions of neutrophils. Higher serum type I IFN levels in AILD patients upregulated IL-18RAP expression in neutrophils, suggesting that type I IFN contributes to the pathogenesis of AILD by upregulating IL-18RAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.